News Releases

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) […]

Read more

Rahway, NJ., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines. If the European Commission (EC) adopts the recommendation, the […]

Read more

Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products Rahway, N.J., February 11, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that S&P Global Animal Health awarded the injectable formulation of BRAVECTO® (fluralaner) the 2024 Best New Companion […]

Read more

The new formulation targets internal and external parasites, expanding the BRAVECTO® portfolio Rahway, NJ, – November 26, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for BRAVECTO® TriUNO, a new formulation of BRAVECTO (fluralaner) for dogs that targets […]

Read more

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease RAHWAY, N.J., June 25, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the USDA approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of […]

Read more

Rahway, NJ., March 18, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK) has announced a continued commitment to rabies elimination through a donation of NOBIVAC® rabies vaccines to the Mission Rabies program, a charity initiative of the Worldwide Veterinary Service (WVS). The donations will continue over the […]

Read more

BRAVECTO eliminated kennel infestations of brown dog ticks (Rhipicephalus sanguineus sensu lato) External imidacloprid/flumethrin collar treatments failed to eliminate all ticks from kennels RAHWAY, N.J., March 15, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of a recent study demonstrating the efficacy of […]

Read more

BRAVECTO rapidly and consistently kills Ixodes scapularis ticks, a vector of the pathogen responsible for Lyme Disease, as compared to Simparica TRIO® RAHWAY, N.J., February 2, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of a recent study demonstrating BRAVECTO® (fluralaner) Chews for […]

Read more